115810-12-3
Chemical Structure
Tubeimoside II
Synonym(s): Tubeimoside-B
- CAS No.: 115810-12-3
- Formula:C63H98O30
- Molecular Weight:1335.43
InChIKey: GBWAAJJGXQJTTA-OVHHGXAJSA-N
SMILES: OC[C@H]1O[C@](O[C@H]2[C@@H](O)C[C@@]3(C)[C@](CC[C@]4(C)[C@]3([H])CC=C5[C@@]4(C)C[C@@H](O)[C@]67[C@@]5([H])CC(C)(C)CC6)([H])[C@@]2(CO)C)([H])[C@@](O[C@@]8([H])[C@H](O)[C@@H](O)[C@](OC(C[C@](O)(C)CC(O[C@]9([H])[C@@H](O[C@@]%10([H])[C@H](O)[C@@H](O)[C@H](O)CO%10)[C@@H](O)[C@@](O[C@]%11([H])[C@@H](O)[C@@H](O)CO[C@@]%11([H])OC7=O)([H])O[C@H]9C)=O)=O)([H])CO8)([H])[C@@H](O)[C@@H]1O
Biological Activity: Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with Kd values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43, and IAV-H1N1/FM1. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections, skin tumors, and sarcoma 180[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tubeimoside II | 99.90% | Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with Kd values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43, and IAV-H1N1/FM1. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections, skin tumors, and sarcoma 180. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tubeimoside II (Standard) | ≥98% | Tubeimoside II (Standard) is the analytical standard of Tubeimoside II. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Chen Y, et al. Tubeimoside II inhibits TGF-β1-induced metastatic progression of human retinoblastoma cells through suppressing redoxosome-dependent EGFR activation. Chem Biol Interact. 2021;335:109367. [Content Brief]
- [2]. Liu X, et al. A new approach to discovering a broad-spectrum anti-respiratory virus drug: Tubeimoside II modulates host factor PACT to potentiate the RIG-I antiviral pathway. Acta Pharm Sin B. 2026;16(5):3109-3127. [Content Brief]
- [3]. Yu TX, et al. Structure-activity relationship of tubeimosides in anti-inflammatory, antitumor, and antitumor-promoting effects. Acta Pharmacol Sin. 2001;22(5):463-468. [Content Brief]
